{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:38:19Z","timestamp":1787701099819,"version":"build-2784847793"},"reference-count":96,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Individual variations in the response to thiopurine-based anticancer drugs are influenced by genetic and environmental factors, making it challenging to optimize dosing and minimize toxicity. Among the key genes involved, genetic variations in the\n                    <jats:italic>nudix hydrolase 15<\/jats:italic>\n                    (\n                    <jats:italic>NUDT15<\/jats:italic>\n                    ) gene affect on thiopurine metabolism, thus influencing drug efficacy and the risk of severe adverse effects, such as myelosuppression, These variations also contribute to inter-individual differences in drug tolerance and clinical outcomes. Despite the recognized impact of\n                    <jats:italic>NUDT15<\/jats:italic>\n                    variations, there has been limited comprehensive exploration of these variants and their clinical significance in thiopurine therapy. This review provides a thorough analysis of\n                    <jats:italic>NUDT15<\/jats:italic>\n                    genetic variants by synthesizing findings from prior clinical studies and employing\n                    <jats:italic>in silico<\/jats:italic>\n                    analyses to predict the functional effects of variants with uncertain significance. Comprehensive analysis of\n                    <jats:italic>NUDT15<\/jats:italic>\n                    variants and their interactions with other metabolic pathways could offer valuable insights for advancing personalized medicine in cancer treatment. This review aims to establish a foundation for integrating\n                    <jats:italic>NUDT15<\/jats:italic>\n                    genetic information into the clinical practice, reducing toxicity, and improved therapeutic outcomes in patients undergoing thiopurine-based chemotherapy.\n                  <\/jats:p>","DOI":"10.1515\/dmpt-2025-0003","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T05:58:06Z","timestamp":1744437486000},"page":"79-88","source":"Crossref","is-referenced-by-count":3,"title":["Genetic variants in\n                    <i>NUDT15<\/i>\n                    gene their clinical implications in cancer therapy"],"prefix":"10.1515","volume":"40","author":[{"given":"Yazun","family":"Jarrar","sequence":"first","affiliation":[{"name":"Department of Basic Medical Sciences, Faculty of Medicine , Al-Balqa Applied University , Al-Salt , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ghishan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, College of Pharmacy , Al-Zaytoonah University of Jordan , Amman , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Khirfan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, College of Pharmacy , Al-Zaytoonah University of Jordan , Amman , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Hakooz","sequence":"additional","affiliation":[{"name":"School of Pharmacy , The University of Jordan , Amman , Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"2025121207003512770_j_dmpt-2025-0003_ref_001","doi-asserted-by":"crossref","unstructured":"Chaparro, M, Ordas, I, Cabre, E, Garcia-Sanchez, V, Bastida, G, Penalva, M, et al.. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis 2013;19:1404\u201310. https:\/\/doi.org\/10.1097\/mib.0b013e318281f28f.","DOI":"10.1097\/MIB.0b013e318281f28f"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_002","doi-asserted-by":"crossref","unstructured":"Bean, RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962;49:592\u20133. https:\/\/doi.org\/10.5694\/j.1326-5377.1962.tb20590.x.","DOI":"10.5694\/j.1326-5377.1962.tb20590.x"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_003","doi-asserted-by":"crossref","unstructured":"Swann, PF, Waters, TR, Moulton, DC, Xu, YZ, Zheng, Q, Edwards, M, et al.. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996;273:1109\u201311. https:\/\/doi.org\/10.1126\/science.273.5278.1109.","DOI":"10.1126\/science.273.5278.1109"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_004","doi-asserted-by":"crossref","unstructured":"Shen, Y, Zhang, L, Piao, S, Li, L, Li, J, Xia, Y, et al.. NUDT1: a potential independent predictor for the prognosis of patients with oral squamous cell carcinoma. J\u00a0Oral Pathol Med 2020;49:210\u20138. https:\/\/doi.org\/10.1111\/jop.12974.","DOI":"10.1111\/jop.12974"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_005","doi-asserted-by":"crossref","unstructured":"Jewell, DP, Truelove, SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974;4:627\u201330. https:\/\/doi.org\/10.1136\/bmj.4.5945.627.","DOI":"10.1136\/bmj.4.5945.627"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_006","doi-asserted-by":"crossref","unstructured":"Jarrar, Y, Musleh, R, Ghanim, M, AbuKhader, I, Jarrar, Q. Assessment of the need for pharmacogenomics education among pharmacists in the West Bank of Palestine. Int J Clin Pract 2021;75:e14435. https:\/\/doi.org\/10.1111\/ijcp.14435.","DOI":"10.1111\/ijcp.14435"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_007","doi-asserted-by":"crossref","unstructured":"Sahasranaman, S, Howard, D, Roy, S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008;64:753\u201367. https:\/\/doi.org\/10.1007\/s00228-008-0478-6.","DOI":"10.1007\/s00228-008-0478-6"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_008","doi-asserted-by":"crossref","unstructured":"Kojima, Y, Hirotsu, Y, Omata, W, Sugimori, M, Takaoka, S, Ashizawa, H, et al.. Influence of NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines. World J Gastroenterol 2018;24:511\u20138. https:\/\/doi.org\/10.3748\/wjg.v24.i4.511.","DOI":"10.3748\/wjg.v24.i4.511"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_009","doi-asserted-by":"crossref","unstructured":"Kornbluth, A, Sachar, DB. Practice parameters committee of the American college of G. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol 2010;105:501\u201323. https:\/\/doi.org\/10.1038\/ajg.2009.727.","DOI":"10.1038\/ajg.2009.727"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_010","doi-asserted-by":"crossref","unstructured":"Boirivant, M, Marini, M, Di Felice, G, Pronio, AM, Montesani, C, Tersigni, R, et al.. Lamina propria T\u00a0cells in Crohn\u2019s disease and other gastrointestinal inflammation show defective CD2\u00a0pathway-induced apoptosis. Gastroenterology 1999;116:557\u201365. https:\/\/doi.org\/10.1016\/s0016-5085(99)70177-0.","DOI":"10.1016\/S0016-5085(99)70177-0"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_011","unstructured":"Breese, E, Braegger, CP, Corrigan, CJ, Walker-Smith, JA, MacDonald, TT. Interleukin-2- and interferon-gamma-secreting T\u00a0cells in normal and diseased human intestinal mucosa. Immunology 1993;78:127\u201331."},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_012","doi-asserted-by":"crossref","unstructured":"Schwab, M, Schaffeler, E, Marx, C, Fischer, C, Lang, T, Behrens, C, et al.. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002;12:429\u201336. https:\/\/doi.org\/10.1097\/00008571-200208000-00003.","DOI":"10.1097\/00008571-200208000-00003"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_013","doi-asserted-by":"crossref","unstructured":"Siegel, CA, Sands, BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther 2005;22:1\u201316. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02520.x.","DOI":"10.1111\/j.1365-2036.2005.02520.x"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_014","doi-asserted-by":"crossref","unstructured":"Gibson, PR, Gearry, RB. Optimizing thiopurine therapy: more weight to the metabolite argument. J\u00a0Gastroenterol Hepatol 2010;25:1592\u20134. https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06472.x.","DOI":"10.1111\/j.1440-1746.2010.06472.x"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_015","doi-asserted-by":"crossref","unstructured":"Dubinsky, MC, Yang, H, Hassard, PV, Seidman, EG, Kam, LY, Abreu, MT, et al.. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904\u201315. https:\/\/doi.org\/10.1053\/gast.2002.32420.","DOI":"10.1053\/gast.2002.32420"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_016","doi-asserted-by":"crossref","unstructured":"Dubinsky, MC, Lamothe, S, Yang, HY, Targan, SR, Sinnett, D, Theoret, Y, et al.. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705\u201313. https:\/\/doi.org\/10.1016\/s0016-5085(00)70140-5.","DOI":"10.1016\/S0016-5085(00)70140-5"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_017","doi-asserted-by":"crossref","unstructured":"Hindorf, U, Lindqvist, M, Hildebrand, H, Fagerberg, U, Almer, S. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006;24:331\u201342. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.02977.x.","DOI":"10.1111\/j.1365-2036.2006.02977.x"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_018","doi-asserted-by":"crossref","unstructured":"Rosenbaum, EH, Cohen, RA, Glatstein, HR. Vaccination of a patient receiving immunosuppressive therapy for lymphosarcoma. JAMA 1966;198:737\u201340. https:\/\/doi.org\/10.1001\/jama.1966.03110200093025.","DOI":"10.1001\/jama.1966.03110200093025"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_019","doi-asserted-by":"crossref","unstructured":"Bonaz, B, Boitard, J, Marteau, P, Lemann, M, Coffin, B, Flourie, B, et al.. Tioguanine in patients with Crohn\u2019s disease intolerant or resistant to azathioprine\/mercaptopurine. Aliment Pharmacol Ther 2003;18:401\u20138. https:\/\/doi.org\/10.1046\/j.1365-2036.2003.01683.x.","DOI":"10.1046\/j.1365-2036.2003.01683.x"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_020","doi-asserted-by":"crossref","unstructured":"Schwab, M, Klotz, U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 2001;40:723\u201351. https:\/\/doi.org\/10.2165\/00003088-200140100-00003.","DOI":"10.2165\/00003088-200140100-00003"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_021","doi-asserted-by":"crossref","unstructured":"Afrin, S, Simms, LA, Lord, A, Radford-Smith, GL. Nudix hydrolase 15 (NUDT15) loss-of-function variants in an Australian inflammatory bowel disease population. Intern Med J 2022;52:1971\u20137. https:\/\/doi.org\/10.1111\/imj.15746.","DOI":"10.1111\/imj.15746"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_022","doi-asserted-by":"crossref","unstructured":"Krynetskaia, NF, Krynetski, EY, Evans, WE. Human RNase H-mediated RNA cleavage from DNA-RNA duplexes is inhibited by 6-deoxythioguanosine incorporation into DNA. Mol Pharmacol 1999;56:841\u20138. https:\/\/doi.org\/10.1016\/s0026-895x(24)12548-5.","DOI":"10.1016\/S0026-895X(24)12548-5"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_023","unstructured":"Tew, KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994;54:4313\u201320."},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_024","doi-asserted-by":"crossref","unstructured":"Moden, O, Zhang, W, Mannervik, B. Mutational analysis of human glutathione transferase A2-2 identifies structural elements supporting high activity with the prodrug azathioprine. Protein Eng Des Sel 2012;25:189\u201397. https:\/\/doi.org\/10.1093\/protein\/gzs006.","DOI":"10.1093\/protein\/gzs006"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_025","doi-asserted-by":"crossref","unstructured":"Hamilton, L, Elion, GB. The fate of 6-mercaptopurine in man. Ann N Y Acad Sci 1954;60:304\u201314. https:\/\/doi.org\/10.1111\/j.1749-6632.1954.tb40021.x.","DOI":"10.1111\/j.1749-6632.1954.tb40021.x"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_026","doi-asserted-by":"crossref","unstructured":"Allan, PW, Bennett, LLJr. 6-Methylthioguanylic acid, a metabolite of 6-thioguanine. Biochem Pharmacol 1971;20:847\u201352. https:\/\/doi.org\/10.1016\/0006-2952(71)90046-3.","DOI":"10.1016\/0006-2952(71)90046-3"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_027","unstructured":"Elion, GB, Callahan, S, Rundles, RW, Hitchings, GH. Relationship between metabolic fates and antitumor activities of thiopurines. Philadelphia: AACR; 1963."},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_028","doi-asserted-by":"crossref","unstructured":"Lennard, L, Lilleyman, JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996;18:328\u201334. https:\/\/doi.org\/10.1097\/00007691-199608000-00003.","DOI":"10.1097\/00007691-199608000-00003"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_029","doi-asserted-by":"crossref","unstructured":"Lichtenstein, GR, Abreu, MT, Cohen, R, Tremaine, W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940\u201387. https:\/\/doi.org\/10.1053\/j.gastro.2006.01.048.","DOI":"10.1053\/j.gastro.2006.01.048"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_030","doi-asserted-by":"crossref","unstructured":"Neurath, MF, Kiesslich, R, Teichgraber, U, Fischer, C, Hofmann, U, Eichelbaum, M, et al.. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn\u2019s disease. Clin Gastroenterol Hepatol 2005;3:1007\u201314. https:\/\/doi.org\/10.1016\/s1542-3565(05)00697-x.","DOI":"10.1016\/S1542-3565(05)00697-X"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_031","unstructured":"Nelson, JA, Carpenter, JW, Rose, LM, Adamson, DJ. Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine. Cancer Res 1975;35:2872\u20138."},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_032","doi-asserted-by":"crossref","unstructured":"Fairchild, CR, Maybaum, J, Kennedy, KA. Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment. Biochem Pharmacol 1986;35:3533\u201341. https:\/\/doi.org\/10.1016\/0006-2952(86)90623-4.","DOI":"10.1016\/0006-2952(86)90623-4"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_033","doi-asserted-by":"crossref","unstructured":"Singh, M, Bhatia, P, Khera, S, Trehan, A. Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia. Leuk Res 2017;62:17\u201322. https:\/\/doi.org\/10.1016\/j.leukres.2017.09.012.","DOI":"10.1016\/j.leukres.2017.09.012"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_034","doi-asserted-by":"crossref","unstructured":"Kakuta, Y, Kinouchi, Y, Shimosegawa, T. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping. J\u00a0Gastroenterol 2018;53:172\u201380. https:\/\/doi.org\/10.1007\/s00535-017-1416-0.","DOI":"10.1007\/s00535-017-1416-0"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_035","doi-asserted-by":"crossref","unstructured":"Colombel, JF, Ferrari, N, Debuysere, H, Marteau, P, Gendre, JP, Bonaz, B, et al.. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn\u2019s disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025\u201330. https:\/\/doi.org\/10.1016\/s0016-5085(00)70354-4.","DOI":"10.1016\/S0016-5085(00)70354-4"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_036","unstructured":"Weinshilboum, RM, Sladek, SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651\u201362."},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_037","doi-asserted-by":"crossref","unstructured":"Spire-Vayron de la Moureyre, C, Debuysere, H, Sabbagh, N, Marez, D, Vinner, E, Chevalier, ED, et al.. Detection of known and new mutations in the thiopurine S-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998;12:177\u201385. https:\/\/doi.org\/10.1002\/(sici)1098-1004(1998)12:3<177::aid-humu5>3.0.co;2-e.","DOI":"10.1002\/(SICI)1098-1004(1998)12:3<177::AID-HUMU5>3.0.CO;2-E"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_038","doi-asserted-by":"crossref","unstructured":"Iu, YPH, Helander, S, Kahlin, AZ, Cheng, CW, Shek, CC, Leung, MH, et al.. One amino acid makes a difference-characterization of a new TPMT allele and the influence of SAM on TPMT stability. Sci Rep 2017;7:46428. https:\/\/doi.org\/10.1038\/srep46428.","DOI":"10.1038\/srep46428"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_039","doi-asserted-by":"crossref","unstructured":"Ujiie, S, Sasaki, T, Mizugaki, M, Ishikawa, M, Hiratsuka, M. Functional characterization of 23 allelic variants of thiopurine S-methyltransferase gene (TPMT*2-*24). Pharmacogenet Genomics 2008;18:887\u201393. https:\/\/doi.org\/10.1097\/fpc.0b013e3283097328.","DOI":"10.1097\/FPC.0b013e3283097328"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_040","doi-asserted-by":"crossref","unstructured":"Nagasaki, M, Yasuda, J, Katsuoka, F, Nariai, N, Kojima, K, Kawai, Y, et al.. Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals. Nat Commun 2015;6:8018. https:\/\/doi.org\/10.1038\/ncomms9018.","DOI":"10.1038\/ncomms9018"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_041","doi-asserted-by":"crossref","unstructured":"McLeod, HL, Pritchard, SC, Githang\u2019a, J, Indalo, A, Ameyaw, MM, Powrie, RH, et al.. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999;9:773\u20136. https:\/\/doi.org\/10.1097\/01213011-199912000-00012.","DOI":"10.1097\/00008571-199912000-00012"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_042","doi-asserted-by":"crossref","unstructured":"Collie-Duguid, ES, Pritchard, SC, Powrie, RH, Sludden, J, Collier, DA, Li, T, et al.. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37\u201342. https:\/\/doi.org\/10.1097\/00008571-199902000-00006.","DOI":"10.1097\/00008571-199902000-00006"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_043","unstructured":"Jun, JB, Cho, DY, Kang, C, Bae, SC. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol 2005;23:873\u20136."},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_044","doi-asserted-by":"crossref","unstructured":"Ranasinghe, P, Sirisena, N, Vishnukanthan, T, Ariadurai, JN, Thilakarathne, S, Priyadarshani, CDN, et al.. Frequency of pharmacogenomic variants affecting efficacy and safety of anti-cancer drugs in a south Asian population from Sri Lanka. BMC Med Genom 2024;17:143. https:\/\/doi.org\/10.1186\/s12920-024-01919-2.","DOI":"10.1186\/s12920-024-01919-2"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_045","doi-asserted-by":"crossref","unstructured":"Takatsu, N, Matsui, T, Murakami, Y, Ishihara, H, Hisabe, T, Nagahama, T, et al.. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J\u00a0Gastroenterol Hepatol 2009;24:1258\u201364. https:\/\/doi.org\/10.1111\/j.1440-1746.2009.05917.x.","DOI":"10.1111\/j.1440-1746.2009.05917.x"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_046","doi-asserted-by":"crossref","unstructured":"Lin, S, McLennan, AG, Ying, K, Wang, Z, Gu, S, Jin, H, et al.. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the ITPA gene. J\u00a0Biol Chem 2001;276:18695\u2013701. https:\/\/doi.org\/10.1074\/jbc.m011084200.","DOI":"10.1074\/jbc.M011084200"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_047","doi-asserted-by":"crossref","unstructured":"Holmes, SL, Turner, BM, Hirschhorn, K. Human inosine triphosphatase: catalytic properties and population studies. Clin Chim Acta 1979;97:143\u201353. https:\/\/doi.org\/10.1016\/0009-8981(79)90410-8.","DOI":"10.1016\/0009-8981(79)90410-8"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_048","doi-asserted-by":"crossref","unstructured":"Sumi, S, Marinaki, AM, Arenas, M, Fairbanks, L, Shobowale-Bakre, M, Rees, DC, et al.. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111:360\u20137. https:\/\/doi.org\/10.1007\/s00439-002-0798-z.","DOI":"10.1007\/s00439-002-0798-z"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_049","doi-asserted-by":"crossref","unstructured":"Uchiyama, K, Nakamura, M, Kubota, T, Yamane, T, Fujise, K, Tajiri, H. Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine\/6-mercaptopurine treatment. J\u00a0Gastroenterol 2009;44:197\u2013203. https:\/\/doi.org\/10.1007\/s00535-008-2307-1.","DOI":"10.1007\/s00535-008-2307-1"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_050","doi-asserted-by":"crossref","unstructured":"Gearry, RB, Roberts, RL, Barclay, ML, Kennedy, MA. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004;14:779\u201381. https:\/\/doi.org\/10.1097\/00008571-200411000-00010.","DOI":"10.1097\/00008571-200411000-00010"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_051","doi-asserted-by":"crossref","unstructured":"Allorge, D, Hamdan, R, Broly, F, Libersa, C, Colombel, JF. ITPA genotyping test does not improve detection of Crohn\u2019s disease patients at risk of azathioprine\/6-mercaptopurine induced myelosuppression. Gut 2005;54:565. https:\/\/doi.org\/10.1136\/gut.2004.055947.","DOI":"10.1136\/gut.2004.055947"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_052","doi-asserted-by":"crossref","unstructured":"Wielinga, PR, Reid, G, Challa, EE, van der Heijden, I, van Deemter, L, de Haas, M, et al.. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5. Mol Pharmacol 2002;62:1321\u20139.","DOI":"10.1124\/mol.62.6.1321"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_053","doi-asserted-by":"crossref","unstructured":"Krishnamurthy, P, Schwab, M, Takenaka, K, Nachagari, D, Morgan, J, Leslie, M, et al.. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 2008;68:4983\u20139. https:\/\/doi.org\/10.1158\/0008-5472.can-07-6790.","DOI":"10.1158\/0008-5472.CAN-07-6790"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_054","doi-asserted-by":"crossref","unstructured":"Ban, H, Andoh, A, Imaeda, H, Kobori, A, Bamba, S, Tsujikawa, T, et al.. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J\u00a0Gastroenterol 2010;45:1014\u201321. https:\/\/doi.org\/10.1007\/s00535-010-0248-y.","DOI":"10.1007\/s00535-010-0248-y"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_055","doi-asserted-by":"crossref","unstructured":"Tanaka, Y, Nakadate, H, Kondoh, K, Nakamura, K, Koh, K, Manabe, A. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia. Pharmacogenomics J 2018;18:275\u201380. https:\/\/doi.org\/10.1038\/tpj.2017.12.","DOI":"10.1038\/tpj.2017.12"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_056","doi-asserted-by":"crossref","unstructured":"Coelho, T, Andreoletti, G, Ashton, JJ, Batra, A, Afzal, NA, Gao, Y, et al.. Genes implicated in thiopurine-induced toxicity: comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort. Sci Rep 2016;6:34658. https:\/\/doi.org\/10.1038\/srep34658.","DOI":"10.1038\/srep34658"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_057","doi-asserted-by":"crossref","unstructured":"Rudd, SG, Valerie, NCK, Helleday, T. Pathways controlling dNTP pools to maintain genome stability. DNA Repair 2016;44:193\u2013204. https:\/\/doi.org\/10.1016\/j.dnarep.2016.05.032.","DOI":"10.1016\/j.dnarep.2016.05.032"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_058","doi-asserted-by":"crossref","unstructured":"Carreras-Puigvert, J, Zitnik, M, Jemth, AS, Carter, M, Unterlass, JE, Hallstrom, B, et al.. A comprehensive structural, biochemical and biological profiling of the human NUDIX hydrolase family. Nat Commun 2017;8:1541. https:\/\/doi.org\/10.1038\/s41467-017-01642-w.","DOI":"10.1038\/s41467-017-01642-w"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_059","doi-asserted-by":"crossref","unstructured":"Pelin, M, De Iudicibus, S, Londero, M, Spizzo, R, Dei Rossi, S, Martelossi, S, et al.. Thiopurine biotransformation and pharmacological effects: contribution of oxidative stress. Curr Drug Metabol 2016;17:542\u20139. https:\/\/doi.org\/10.2174\/1389200217666160303104153.","DOI":"10.2174\/1389200217666160303104153"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_060","doi-asserted-by":"crossref","unstructured":"McLennan, AG. The Nudix hydrolase superfamily. Cell Mol Life Sci 2006;63:123\u201343. https:\/\/doi.org\/10.1007\/s00018-005-5386-7.","DOI":"10.1007\/s00018-005-5386-7"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_061","doi-asserted-by":"crossref","unstructured":"Bessman, MJ, Frick, DN, O\u2019Handley, SF. The MutT proteins or \u201cNudix\u201d hydrolases, a family of versatile, widely distributed, \u201chousecleaning\u201d enzymes. J\u00a0Biol Chem 1996;271:25059\u201362. https:\/\/doi.org\/10.1074\/jbc.271.41.25059.","DOI":"10.1074\/jbc.271.41.25059"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_062","doi-asserted-by":"crossref","unstructured":"Mildvan, AS, Xia, Z, Azurmendi, HF, Saraswat, V, Legler, PM, Massiah, MA, et al.. Structures and mechanisms of Nudix hydrolases. Arch Biochem Biophys 2005;433:129\u201343. https:\/\/doi.org\/10.1016\/j.abb.2004.08.017.","DOI":"10.1016\/j.abb.2004.08.017"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_063","doi-asserted-by":"crossref","unstructured":"Xu, W, Dunn, CA, Jones, CR, D\u2019Souza, G, Bessman, MJ. The 26 Nudix hydrolases of Bacillus cereus, a close relative of Bacillus anthracis. J\u00a0Biol Chem 2004;279:24861\u20135. https:\/\/doi.org\/10.1074\/jbc.m403272200.","DOI":"10.1074\/jbc.M403272200"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_064","doi-asserted-by":"crossref","unstructured":"Li, DN, Yang, CC, Li, J, Ou Yang, QG, Zeng, LT, Fan, GQ, et al.. The high expression of MTH1 and NUDT5 promotes tumor metastasis and indicates a poor prognosis in patients with non-small-cell lung cancer. Biochim Biophys Acta Mol Cell Res 2021;1868:118895. https:\/\/doi.org\/10.1016\/j.bbamcr.2020.118895.","DOI":"10.1016\/j.bbamcr.2020.118895"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_065","doi-asserted-by":"crossref","unstructured":"Kamiya, H, Yakushiji, H, Dugue, L, Tanimoto, M, Pochet, S, Nakabeppu, Y, et al.. Probing the substrate recognition mechanism of the human MTH1 protein by nucleotide analogs. J\u00a0Mol Biol 2004;336:843\u201350. https:\/\/doi.org\/10.1016\/j.jmb.2003.12.060.","DOI":"10.1016\/j.jmb.2003.12.060"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_066","doi-asserted-by":"crossref","unstructured":"Kang, D, Nishida, J, Iyama, A, Nakabeppu, Y, Furuichi, M, Fujiwara, T, et al.. Intracellular localization of 8-oxo-dGTPase in human cells, with special reference to the role of the enzyme in mitochondria. J\u00a0Biol Chem 1995;270:14659\u201365. https:\/\/doi.org\/10.1074\/jbc.270.24.14659.","DOI":"10.1074\/jbc.270.24.14659"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_067","doi-asserted-by":"crossref","unstructured":"Shimura-Miura, H, Hattori, N, Kang, D, Miyako, K, Nakabeppu, Y, Mizuno, Y. Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson\u2019s disease. Ann Neurol 1999;46:920\u20134. https:\/\/doi.org\/10.1002\/1531-8249(199912)46:6<920::aid-ana17>3.3.co;2-i.","DOI":"10.1002\/1531-8249(199912)46:6<920::AID-ANA17>3.3.CO;2-I"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_068","doi-asserted-by":"crossref","unstructured":"Fujikawa, K, Kamiya, H, Yakushiji, H, Fujii, Y, Nakabeppu, Y, Kasai, H. The oxidized forms of dATP are substrates for the human MutT homologue, the hMTH1 protein. J\u00a0Biol Chem 1999;274:18201\u20135. https:\/\/doi.org\/10.1074\/jbc.274.26.18201.","DOI":"10.1074\/jbc.274.26.18201"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_069","doi-asserted-by":"crossref","unstructured":"Guranowski, A. Specific and nonspecific enzymes involved in the catabolism of mononucleoside and dinucleoside polyphosphates. Pharmacol Ther 2000;87:117\u201339. https:\/\/doi.org\/10.1016\/s0163-7258(00)00046-2.","DOI":"10.1016\/S0163-7258(00)00046-2"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_070","doi-asserted-by":"crossref","unstructured":"Kitamoto, A, Kitamoto, T, Mizusawa, S, Teranishi, H, So, R, Matsuo, T, et al.. NUDT3 rs206936 is associated with body mass index in obese Japanese women. Endocr J 2013;60:991\u20131000. https:\/\/doi.org\/10.1507\/endocrj.ej13-0100.","DOI":"10.1507\/endocrj.EJ13-0100"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_071","doi-asserted-by":"crossref","unstructured":"Carter, M, Jemth, AS, Hagenkort, A, Page, BD, Gustafsson, R, Griese, JJ, et al.. Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2. Nat Commun 2015;6:7871. https:\/\/doi.org\/10.1038\/ncomms8871.","DOI":"10.1038\/ncomms8871"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_072","doi-asserted-by":"crossref","unstructured":"Cai, JP, Ishibashi, T, Takagi, Y, Hayakawa, H, Sekiguchi, M. Mouse MTH2 protein which prevents mutations caused by 8-oxoguanine nucleotides. Biochem Biophys Res Commun 2003;305:1073\u20137. https:\/\/doi.org\/10.1016\/s0006-291x(03)00864-7.","DOI":"10.1016\/S0006-291X(03)00864-7"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_073","doi-asserted-by":"crossref","unstructured":"Moriyama, T, Nishii, R, Perez-Andreu, V, Yang, W, Klussmann, FA, Zhao, X, et al.. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 2015;47:367. https:\/\/doi.org\/10.1038\/ng.3508.","DOI":"10.1038\/ng.3508"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_074","doi-asserted-by":"crossref","unstructured":"Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329\u201339. https:\/\/doi.org\/10.1007\/bf02220605.","DOI":"10.1007\/BF02220605"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_075","unstructured":"Warren, DJ, Andersen, A, Sl\u00f8rdal, L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res 1995;55:1670\u20134."},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_076","unstructured":"Yan, T, Berry, SE, Desai, AB, Kinsella, TJ. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells. Clin Cancer Res 2003;9:2327\u201334."},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_077","doi-asserted-by":"crossref","unstructured":"Svensson, LM, Jemth, AS, Desroses, M, Loseva, O, Helleday, T, Hogbom, M, et al.. Crystal structure of human MTH1 and the 8-oxo-dGMP product complex. FEBS Lett 2011;585:2617\u201321. https:\/\/doi.org\/10.1016\/j.febslet.2011.07.017.","DOI":"10.1016\/j.febslet.2011.07.017"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_078","doi-asserted-by":"crossref","unstructured":"Yang, JJ, Landier, W, Yang, W, Liu, C, Hageman, L, Cheng, C, et al.. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J\u00a0Clin Oncol 2015;33:1235\u201342. https:\/\/doi.org\/10.1200\/jco.2014.59.4671.","DOI":"10.1200\/JCO.2014.59.4671"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_079","doi-asserted-by":"crossref","unstructured":"Yang, SK, Hong, M, Baek, J, Choi, H, Zhao, W, Jung, Y, et al.. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 2014;46:1017\u201320. https:\/\/doi.org\/10.1038\/ng.3060.","DOI":"10.1038\/ng.3060"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_080","doi-asserted-by":"crossref","unstructured":"Zhu, X, Wang, XD, Chao, K, Zhi, M, Zheng, H, Ruan, HL, et al.. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine\u2010induced leukopenia in Chinese patients with Crohn\u2019s disease. Aliment Pharmacol Ther 2016;44:967\u201375. https:\/\/doi.org\/10.1111\/apt.13796.","DOI":"10.1111\/apt.13796"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_081","doi-asserted-by":"crossref","unstructured":"Lee, YJ, Hwang, EH, Park, JH, Shin, JH, Kang, B, Kim, SY. NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn\u2019s disease. Eur J Gastroenterol Hepatol 2016;28:475\u20138. https:\/\/doi.org\/10.1097\/meg.0000000000000564.","DOI":"10.1097\/MEG.0000000000000564"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_082","doi-asserted-by":"crossref","unstructured":"Makuuchi, M, Kakuta, Y, Umeno, J, Fujii, T, Takagawa, T, Ibuka, T, et al.. Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study. J\u00a0Gastroenterol 2024;59:468\u201382. https:\/\/doi.org\/10.1007\/s00535-024-02099-7.","DOI":"10.1007\/s00535-024-02099-7"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_083","doi-asserted-by":"crossref","unstructured":"Asada, A, Nishida, A, Shioya, M, Imaeda, H, Inatomi, O, Bamba, S, et al.. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. J\u00a0Gastroenterol 2016;51:22\u20139. https:\/\/doi.org\/10.1007\/s00535-015-1142-4.","DOI":"10.1007\/s00535-015-1142-4"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_084","doi-asserted-by":"crossref","unstructured":"Yi, ES, Choi, YB, Choi, R, Lee, NH, Lee, JW, Yoo, KH, et al.. NUDT15 variants cause hematopoietic toxicity with low 6-TGN levels in children with acute lymphoblastic leukemia. Cancer Res Treat. 2018;50:872-82.85.","DOI":"10.4143\/crt.2017.283"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_085","doi-asserted-by":"crossref","unstructured":"Moriyama, T, Nishii, R, Lin, TN, Kihira, K, Toyoda, H, Jacob, N, et al.. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2017;27:236\u20139. https:\/\/doi.org\/10.1097\/fpc.0000000000000282.","DOI":"10.1097\/FPC.0000000000000282"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_086","doi-asserted-by":"crossref","unstructured":"Jarrar, YB, Ghishan, M. The Nudix hydrolase 15 (NUDT15) gene variants among Jordanian Arab population. Asian Pac J Cancer Prev APJCP 2019;20:801\u20138. https:\/\/doi.org\/10.31557\/apjcp.2019.20.3.801.","DOI":"10.31557\/APJCP.2019.20.3.801"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_087","doi-asserted-by":"crossref","unstructured":"Sabirova, Z, Mahnoor, S, Lasfar, D, Gagn\u00e9, V, Th\u00e9or\u00eat, Y, Leclerc, JM, et al.. Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients. Pharmacogenet Genomics 2024;34:170\u20133. https:\/\/doi.org\/10.1097\/fpc.0000000000000533.","DOI":"10.1097\/FPC.0000000000000533"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_088","doi-asserted-by":"crossref","unstructured":"Hartl, FU, Bracher, A, Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. Nature 2011;475:324\u201332. https:\/\/doi.org\/10.1038\/nature10317.","DOI":"10.1038\/nature10317"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_089","doi-asserted-by":"crossref","unstructured":"Zhou, H, Li, L, Yang, P, Yang, L, Zheng, JE, Zhou, Y, et al.. Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? BMC Cancer 2018;18:516. https:\/\/doi.org\/10.1186\/s12885-018-4398-2.","DOI":"10.1186\/s12885-018-4398-2"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_090","doi-asserted-by":"crossref","unstructured":"Chiengthong, K, Ittiwut, C, Muensri, S, Sophonphan, J, Sosothikul, D, Seksan, P, et al.. NUDT15 c.415C>T increases risk of 6-mercaptopurine-induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica 2016;101:e24\u201326. https:\/\/doi.org\/10.3324\/haematol.2015.134775.","DOI":"10.3324\/haematol.2015.134775"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_091","doi-asserted-by":"crossref","unstructured":"Lee, JH, Kim, TJ, Kim, ER, Hong, SN, Chang, DK, Choi, LH, et al.. Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn\u2019s disease. PLoS One 2017;12:e0188925. https:\/\/doi.org\/10.1371\/journal.pone.0188925.","DOI":"10.1371\/journal.pone.0188925"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_092","doi-asserted-by":"crossref","unstructured":"Mitra, S, Ghosh, A, Chatterjee, S, Chatterjee, M, Sinhamahapatra, P. Association of TPMT and NUDT15 gene polymorphisms with azathioprine-induced leukopenia: a case-control study in Eastern India. Indian J Pharmacol 2024;56:166\u201371. https:\/\/doi.org\/10.4103\/ijp.ijp_764_23.","DOI":"10.4103\/ijp.ijp_764_23"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_093","doi-asserted-by":"crossref","unstructured":"Suzuki, H, Fukushima, H, Suzuki, R, Hosaka, S, Yamaki, Y, Kobayashi, C, et al.. Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age. J\u00a0Hum Genet 2016;61:797\u2013801. https:\/\/doi.org\/10.1038\/jhg.2016.55.","DOI":"10.1038\/jhg.2016.55"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_094","doi-asserted-by":"crossref","unstructured":"Moriyama, T, Yang, YL, Nishii, R, Ariffin, H, Liu, C, Lin, TN, et al.. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry. Blood 2017;130:1209\u201312. https:\/\/doi.org\/10.1182\/blood-2017-05-782383.","DOI":"10.1182\/blood-2017-05-782383"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_095","doi-asserted-by":"crossref","unstructured":"Whirl-Carrillo, M, Huddart, R, Gong, L, Sangkuhl, K, Thorn, CF, Whaley, R, et al.. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2021;110:563\u201372. https:\/\/doi.org\/10.1002\/cpt.2350.","DOI":"10.1002\/cpt.2350"},{"key":"2025121207003512770_j_dmpt-2025-0003_ref_096","doi-asserted-by":"crossref","unstructured":"Relling, MV, Schwab, M, Whirl-Carrillo, M, Suarez-Kurtz, G, Pui, CH, Stein, CM, et al.. Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 2019;105:1095\u2013105. https:\/\/doi.org\/10.1002\/cpt.1304.","DOI":"10.1002\/cpt.1304"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0003\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0003\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:33:40Z","timestamp":1765524820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2025-0003\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":96,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,2]]},"published-print":{"date-parts":[[2025,6,26]]}},"alternative-id":["10.1515\/dmpt-2025-0003"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2025-0003","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]}}}